EMA Revoked: Dimethyl fumarate Teva (dimethyl fumarate) — Teva GmbH

View source ↗

Summary

EMA revoked the marketing authorization for Teva's dimethyl fumarate product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Multiple Sclerosis Relapsing-remitting

Drugs mentioned

• Dimethyl fumarate Teva (dimethyl fumarate)

Snippet

Status: Revoked. Therapeutic area: Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis. MAH: Teva GmbH. Decision date: 12/12/2023